Trials / Conditions / Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
5 registered clinical trials studyying Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia NCT03589326 | Takeda | Phase 3 |
| Recruiting | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917 | Marlise Luskin, MD | Phase 1 |
| Completed | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic NCT01667133 | Ariad Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® In NCT01066468 | Novartis Pharmaceuticals | Phase 1 |
| Approved For Marketing | Expanded Access Program of Ponatinib NCT01592136 | Ariad Pharmaceuticals | — |